Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Semaglutide in type 2 diabetes with chronic kidney disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, semaglutide also significantly reduced the rate of eGFR decline (annual slope difference 1•16 mL/min per 1•73 m², 0•86-1•47), MACE (HR 0•82, 0•68-0•98), and all-cause mortality (HR 0•80, 0•67-0•95)”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Treatment with injectable semaglutide 1 mg once weekly reduced the relative risk for the composite primary outcome (ie, ≥50% eGFR decline, eGFR <15 mL/min per 1•73 m², dialysis or transplant, or death due to kidney disease or cardiovascular disease) by 24% compared with placebo (HR 0•76, 0•66-0•88).26”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Moreover, the GLP-1 receptor agonist, semaglutide reduced the risk of a composite kidney end point in a dedicated kidney outcome trial.11”
From The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity (2025) · cites this paper as [11]
In the citing paper
“semaglutide can reduce the progression of chronic kidney disease in patients with and without diabetes and even in those taking SGLT2 inhibitors [12–14].”
From New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? (2025) · cites this paper as [13]
In the citing paper
“Once-weekly treatment with 1 mg semaglutide reduced the risk of the primary composite outcome by 24% and delayed the progression of kidney dysfunction over a period of 4 years (75).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [75]
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Bikbov, B., Purcell, C. A., Levey, A. S., Smith, M., Abdoli, A., Abebe, M., Adebayo, O. M., Afarideh, M., Agarwal, S. K., Agudelo-Botero, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30045-3 · Cited by 6,648
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationEmpagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754
Cardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Self-citation
Cited by
Items 301–400 of 1,871
CKDs at the Crossroads: From Failures to Future Therapies
Wehbe, F., Elliott, M., & Levin, A. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.09.050 · Cited by 17
Chronic Kidney Disease in Diabetes: A Clinical Practice Guideline
Tobe, S. W., BAJAJ, H. S., Tangri, N., Jain, R., Pham, T. T., Beaudin, V., & McFarlane, P. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.01.004 · Cited by 23
A New Era in Diabetic Kidney Disease Treatment: The Four Pillars and Strategies to Build Beyond
Han, S., & Kim, S. (2024) · Electrolytes & Blood Pressure · doi:10.5049/ebp.2024.22.2.21 · Cited by 17
“Semaglutide was shown to induce 24% reduction of kidney related outcomes (albuminuria, low eGFR, initiation of RRT, kidney related death) in the FLOW trial 16) and the SUSTAIN 6 trial 15) .”
Wanner, C., Zhao, M., Amin, A., Nicola, L. D., Sauer, A. J., Allum, A. M., Aranda, U., Nam, Y., & Butler, J. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03228-1 · Cited by 23
“In FLOW, treatment with semaglutide provided a significant reduction in major kidney disease events compared with placebo [53, 54].”
InfluentialLee, K. A., Kim, J. S., Kim, Y. J., Goak, I. S., Jin, H. Y., Park, S. Y., Kang, H., & Park, T. S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14062065 · Cited by 19
Siddiqui, H. F., Ali, D., Sajid, M., Qureshi, S., Siddiqui, H., Hasan, A., Ripley, D. P., Ahmed, R., & Waqas, S. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70123 · Cited by 22
An Updated Comprehensive Review on Diseases Associated with Nephrotic Syndromes
Wendt, R. T., Sobhani, A., Diefenhardt, P., Trappe, M., & Völker, L. A. (2024) · Biomedicines · doi:10.3390/biomedicines12102259 · Cited by 33
“Further therapeutic developments included the introduction of nsMRAs (Finerenone) with evidence for renal protection [155–157] as well as new data for renal benefits with GLP1-R agonists [158].”
BackgroundEvolving strategies for early diagnosis, proactive prevention and treatment of CKD
Ortíz, A., Yanagita, M., Yokoi, H., & Torrá, R. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf151 · Cited by 27
Incretins and the cardiovascular system: bridging digestion with metabolism
Avogaro, A., & Fadini, G. P. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00166-4 · Cited by 21
Contemporary treatment options in heart failure with preserved ejection fraction
Peikert, A., & Solomon, S. D. (2024) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeae201 · Cited by 15
Kovesdy, C. P., Ebert, N., Vizcaya, D., Walsh, M., Kosiborod, M., Layton, J. B., ZIEMIECKI, R. M., Johannes, C. B., Pladevall, M., Gee, P. O., et al. (2025) · The Nephron journals/Nephron journals · doi:10.1159/000543923 · Cited by 14
“Just recently, in patients with predominantly very high degree of albuminuria, semaglutide showed a bene fi t for renal protection [25].”
Tuttle, K. R., Reynolds, C. L., Kornowske, L. M., Jones, C. R., Alicic, R. Z., Daratha, K. B., Neumiller, J. J., Greenbaum, C. J., Pavkov, M. E., Xu, F. Z., et al. (2025) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2025.101130 · Cited by 13
Self-citationKarakasis, P., Koufakis, T., Patoulias, D., Barkas, F., Klisic, A. N., Mitrović, M., Doumas, M. N., Παπάνας, Ν., & Popovic, D. S. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15979 · Cited by 20
“…kidney disease, according to evidence retrieved for the first in literature, hallmark, FLOW trial, which demonstrated a significant reduction in the risk for the composite kidney outcome, 34 further expanding their use beyond individuals with established atherosclerotic cardiovascular disease.”
Hasebe, M., Su, C., Keidai, Y., Minamino, H., Yabe, D., Inagaki, N., & Yoshiji, S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70121 · Cited by 16
“7,8 Together, these trials contributed more than 13 000 additional participants, corresponding to an increase of over 20% compared with our 2022 analysis.”
Incretin-Based Therapies Through the Decades: Molecular Innovations and Clinical Impact
Lee, A. A., Khotina, V. A., Kashirskikh, D. A., Voronko, O. E., Gasanov, V. A. O., & Vasiliev, A. V. (2025) · Medical Sciences · doi:10.3390/medsci13040269 · Cited by 26
Semaglutide and heart failure: Updated meta-analysis.
Barbagelata, L., Masson, W. M., Lobo, M., & Bluro, I. M. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102721 · Cited by 13
Glucagon-like peptide-1 receptor agonism and end-organ protection
Daniels, S. J., Karlsson, C., Schrauwen, P., & Parker, V. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.01.002 · Cited by 20
STOUGAARD, E. B., Andersen, M. R., Bagger, J. I., Søndergaard, E., Østergaard, J. A., Curovic, V. R., Persson, F., Almdal, T., Mathiesen, A. S., Andries, A., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16606 · Cited by 14
“7 12 Current guidelines, therefore, recommend multifactorial treatment including management of multiple risk factors and use of GLP-1RAs, SGLTis and nsMRAs to minimize the risk of CVD and CKD progression, making personalized treatment regiments reachable in this population.”
Self-citationFinerenone in diabetic kidney disease: a new frontier for slowing disease progression
Alhomoud, I. S., Albekery, M. A., Alqadi, R., Alqumia, A., Khan, R. A., Sahlawi, M. A. A., & Mulhim, M. Y. A. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1580645 · Cited by 17
Personalized Antifibrotic Therapy in CKD Progression
Delrue, C., Eisenga, M. F., Delanghe, J., & Speeckaert, M. M. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14121141 · Cited by 15
“In the FLOW trial, semaglutide demonstrated renal-protective properties in people with type 2 diabetes (T2D) and CKD [5].”
Pearce, L., Galán‐Arriola, C., Bell, R., Carr, R. D., Cunningham, J., Davidson, S. M., Ghosh, A. K., Giesz, S., Golforoush, P. A., Gourine, A. V., et al. (2024) · Basic Research in Cardiology · doi:10.1007/s00395-024-01094-6 · Cited by 16
von Samson‐Himmelstjerna, F. A., Steiger, E., Kolbrink, B., Wülfrath, H. S., Czihal, T., Schmitt, R., von Stillfried, D., & Schulte, K. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.101111 · Cited by 16
“…grown lately, as renin-angiotensin system inhibitors, 9 sodium-glucose cotransporter-2 inhibitors, 10 and (in diabetic patients) glucagon-like peptide-1 receptor agonists 11 and miner-alocorticoid receptor antagonists 12 signi fi cantly halted the progression of CKD in prospective randomized trials.”
Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea
D’Annibale, D. A., Mimoto, M. S., McCowen, K. C., & Malhotra, A. (2025) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001208 · Cited by 13
Chi, K.-Y., Song, J., Desphande, S., Lee, P., Soni, A., Gonzales-Uribe, A., Lessa, Y., Morgan, A. A., Chang, Y., Lin, Y.-S., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.17541 · Cited by 14
Management of Elderly Patients with Chronic Kidney Disease
Park, Y., & Hwang, W. M. (2024) · Yonsei Medical Journal · doi:10.3349/ymj.2024.0178 · Cited by 19
Beaudrey, T., Bedo, D., Weschler, C., Caillard, S., & Florens, N. (2025) · Diagnostics · doi:10.3390/diagnostics15070802 · Cited by 21
“GLP-1 receptor agonists are another first-line option, supported by recent studies demonstrating their cardiovascular benefits [125,126] and tolerability in KTRs [127].”
Adipocentric Strategy for the Treatment of Type 2 Diabetes Mellitus
Martínez, J. J. G. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030678 · Cited by 16
Meng, L., Li, Z., Xu, L., Wei, F., Ji, H., Zhang, L., Zhu, A., & Zhou, Z. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1728293 · Cited by 21
Tuccinardi, D., Zilich, R., Ponzani, P., Musacchio, N., Manicardi, V., Rocca, A., Pontremoli, R., Fioretto, P., Muscarà, A., Cianni, G. D., et al. (2025) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00251-7 · Cited by 12
“Conversely, individuals with lower BMI might be less likely to receive GLP-1RAs, despite strong evidence that their cardiorenal benefits go beyond weight reduction [15–17].”
InfluentialNew pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024
Tamargo, J. L., Agewall, S., Ambrosio, G., Borghi, C., Cerbai, E., Dan, G. A., Drexel, H., Ferdinándy, P., Grove, E. L., Klingenberg, R., et al. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf012 · Cited by 18
Semaglutide for Chronic Kidney Disease in Type 2 Diabetes
Passos, R. D. H., Narciso, R. C., & da Silva, A. A. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2410532 · Cited by 12
Ceron, E. L., Reddy, S. D., Kattamuri, L. P. V., Muvva, D. M., Chozet, L. E., & Bright, T. M. (2025) · Journal of Brown Hospital Medicine · doi:10.56305/001c.132255 · Cited by 20
Lee, Y.-J., Fang, Y., Chen, M., Liou, H., Li, T.-H., & Tsai, M. (2025) · Journal of Autoimmunity · doi:10.1016/j.jaut.2025.103453 · Cited by 20
Expanding applications of therapies based on GLP1
Drucker, D. J. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01066-9 · Cited by 18
“• Semaglutide improves cardiovascular and renal outcomes in people with type 2 diabetes mellitus and chronic kidney disease 3 .”
Central nervous system pathways targeted by amylin in the regulation of food intake
Hankir, M. K., & Foll, C. L. (2024) · Biochimie · doi:10.1016/j.biochi.2024.10.012 · Cited by 14
Tuo, J., Li, Z., & Xie, L. (2025) · BMC Nephrology · doi:10.1186/s12882-025-03984-w · Cited by 15
“The coexistence of CKD and diabetes is very common, with about 30% of patients with type 1 diabetes and 50% of those with type 2 diabetes developing CKD [3, 4].”
CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1
Verma, S., Bøttcher, M., Brown, P., Dicker, D., Rubino, D., Sbraccia, P., Sharma, A. M., Smedegaard, L., Sørrig, R., & Garvey, W. T. (2025) · Hypertension · doi:10.1161/hypertensionaha.125.26055 · Cited by 15
Chiang, C., Chang, Y., Yu, C.-C., See, X. Y., Wang, T. H., Xanthavanij, N., Song, J., Lo, S., Chiang, C.-H., Lake, L. L., et al. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.06.020 · Cited by 15
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes
Guo, L., Zhang, B., Xue, X., Zhang, B., Cai, H., Jiang, H., Zhang, L., Jin, P., Wang, X., Cheng, Z., et al. (2025) · Nature · doi:10.1038/s41586-025-10031-z · Cited by 21
XU, Y., Malek, N. D., Chang, A. R., Echouffo-Tcheugui, J. B., Selvin, E., Grams, M. E., Fang, M., & Shin, J. (2026) · Nature Medicine · doi:10.1038/s41591-026-04274-0 · Cited by 22
Kidney Disease: The Forgotten Legacy of Type 1 Diabetes
Thomas, M. C., Zoungas, S., Hanssen, N. M. J., McAuley, S. A., & Cooper, M. E. (2025) · Diabetes Care · doi:10.2337/dci25-0028 · Cited by 20
Vetrugno, L., Deana, C., Porto, A. D., Boero, E., Bellini, V., Biasucci, D. G., & Bignami, E. G. (2025) · Journal of Anesthesia Analgesia and Critical Care · doi:10.1186/s44158-025-00237-y · Cited by 14
Ravikulan, R., Chavali, S., Gunton, J. E., & Pasquale, C. G. D. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70085 · Cited by 15
Diabetic Kidney Disease — Semaglutide Flows into the Mainstream
Herrington, W. G., & Haynes, R. (2024) · New England Journal of Medicine · doi:10.1056/nejme2406408 · Cited by 11
What will the impact be of use of tirzepatide in patients with obstructive sleep apnea (OSA)?
Pack, A. I., Grunstein, R. R., Mokhlesi, B., Ryan, S., Schwab, R., & Gozal, D. (2025) · SLEEP · doi:10.1093/sleep/zsaf045 · Cited by 14
Vranken, N. P. A., Li, X., Bouman, H. J., Mourmans, S. G. J., Achten, A., Aizpurua, A. B., Rocca, H. B., Knackstedt, C., van Empel, V. P. M., & Weerts, J. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02708-6 · Cited by 15
Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Case-Based Narrative Review
Javaid, A., Hariri, E. H., Özkan, B., Lang, K., Khan, S. S., Rangaswami, J., Stone, N. J., Blumenthal, R. S., & Ndumele, C. E. (2025) · American Journal of Medicine Open · doi:10.1016/j.ajmo.2025.100089 · Cited by 15
SGLT-2 Inhibitors and GLP-1 Receptor Agonists as Combination Therapy in Type 2 Diabetes
Liakos, A., Karagiannis, T., Avgerinos, I., & Bekiari, E. (2026) · Current Diabetes Reports · doi:10.1007/s11892-025-01616-z · Cited by 21
“In contrast, relevant data for GLP-1 receptor agonists are limited to the recently published FLOW trial, which demonstrated substantial cardiorenal benefits with subcutaneous semaglu - tide in people with type 2 diabetes and CKD [22 ].”
Bauersachs, J. K., Kato, E. T., & Rangaswami, J. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15345 · Cited by 12
“4,33,37 Figure 2 Shared risk factors and pathogenic mechanisms of CKD and HF. 33,34 CKD, chronic kidney disease, CVD, cardiovascular disease, GLP-1, glucagon-like peptide-1; HF, heart failure, RAS, renin – angiotensin system; SGLT2, sodium-glucose cotransporter 2.”
InfluentialWaqas, S. A., Ali, D., Afridi, M. K., Siddiqui, H. F., Nazir, A., Greene, S. J., & Khan, M. S. (2025) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2025.105981 · Cited by 11
Athinarayanan, S. J., Roberts, C. G. P., Phinney, S. D., Weimbs, T., Friedman, A. N., & Volek, J. S. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1609737 · Cited by 11
The potential role of finerenone in patients with type 1 diabetes and chronic kidney disease
Vasco, M. A. E., Fantaye, S. H., Raghunathan, S., & Solis‐Herrera, C. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15773 · Cited by 13
Alammari, N. A., ALSHEHRI, A. S., Khalaf, A. A., Alamri, R., Alhalal, N., Sultan, M. A. A., Ogran, N., Aljohani, R., Alasmari, S. M. S., Alsharif, S. B., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16476 · Cited by 13
Evén, G., Stenfors, T., Jacobson, S. H., Jernberg, T., Franzén‐Dahlin, Å., Jäghult, S., Kahan, T., & Spaak, J. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae331 · Cited by 14
Proteomic Assessment of the Risk of Secondary Cardiovascular Events among Individuals with CKD
Deo, R., Dubin, R. F., Ren, Y., Wang, J., Feldman, H. I., Shou, H., Coresh, J., Grams, M. E., Surapaneni, A., Cohen, J. B., et al. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000502 · Cited by 11
Kidney Status and Events Preceding Death in Heart Failure: A Real-World Nationwide Study
Zahir, D., Garred, C. H., Carlson, N., Fosbøl, E. L., Elmegaard, M., Jhund, P. S., McMurray, J. J. V., Petrie, M. C., Køber, L., & Schou, M. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3631 · Cited by 11
“Similarly, kidney-related deaths were minimally reported in CKD trials 34 .”
Allahwala, M. A., Marathe, C. S., Nelson, A. J., Psaltis, P. J., & Marathe, J. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.07.005 · Cited by 17
Effect of GLP1 Agonists on Reproduction
Couldwell, M., Tidwell, A. J., & Taylor, A. E. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf401 · Cited by 16
GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease
Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01036-y · Cited by 22
Self-citationTheodorakis, N., Nikolaou, M., & Krentz, A. J. (2025) · Biomolecules · doi:10.3390/biom15030373 · Cited by 15
“Furthermore, the FLOW trial demonstrated that semaglutide improves both renal and cardiovascular hard endpoints in patients with diabetic nephropathy, regardless of body mass index [29].”
Kidney Disease and Heart Failure: Recent Advances and Current Challenges
Lam, C. S. P., Bozkurt, B., Cherney, D. Z. I., Ezekowitz, J. A., Jardine, M., Khan, S. S., Madero, M., Sarnak, M. J., ter Maaten, J. M., Cheung, M., et al. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.102943 · Cited by 21
Self-citationLiabeuf, S., Minutolo, R., Floege, J., & Zoccali, C. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae380 · Cited by 21
The multifaceted effects of semaglutide: exploring its broad therapeutic applications
Alkhatib, M., Almasri, N., Alshwayyat, S., Almahariq, H., Hammadeh, B. M., Taimeh, Z., Alkhatib, L., Alshwayat, A. R. I., Saadeh, N. A., & Al‐kurdi, M. A. (2025) · Future Science OA · doi:10.1080/20565623.2025.2483607 · Cited by 17
“Semaglutide has a protective effect on the kidneys of patients with type 2 diabetes and chronic kidney disease (cKD), mitigating severe outcomes such as significant declines in estimated glomerular filtration rate (eGFR) and kidney function loss [22].”
Wookey, O., Galligan, A., Wilkie, B. D., MacIsaac, A., & Paratz, E. D. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2024.11.025 · Cited by 12
GLP-1 and the cardiovascular system
Kahles, F., Birkenfeld, A. L., & Marx, N. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194748 · Cited by 14
“Given the high risk of individuals with T2D and chronic kidney disease (CKD) to develop heart failure as well as the impaired prognosis of patients with all three comorbidities, data from the FLOW trial are of particular interest (87).”
Semaglutide versus other GLP-1 receptor agonists in patients with MASLD
Kuo, C.-C., Li, C., Chuang, M., Huang, P., Kuo, H., & Lai, C. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000747 · Cited by 16
Management of Peripheral Artery Disease in Adults With Diabetes: 2025 ACC Scientific Statement
Das, S. R., Bonaca, M. P., Creager, M. A., Maruthur, N. M., Nordanstig, J., Pop‐Busui, R., & Ujueta, F. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.11.027 · Cited by 30
GLP1R Gene Expression and Kidney Disease Progression
Triozzi, J. L., Yu, Z., Giri, A., Chen, H., Wilson, O. D., Ferolito, B. R., Ikizler, T. A., Akwo, E. A., Robinson‐Cohen, C., Gaziano, J. M., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.40286 · Cited by 11
Wen, J., Razick, A. A., How-Volkman, C., Bernstein, E., Nadora, D., Truong, A., Razick, D., Akhtar, M., Karabala, M., & Frezza, E. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16110 · Cited by 17
“9,10 11 – 13 However, there has been a shortage of these drugs worldwide, with demand vastly exceeding current production levels.”
Incretin-Based Therapies: A Paradigm Shift in Blood Pressure Management?
Dreher, L., Kylies, D., Danser, A. H. J., & Wenzel, U. O. (2025) · Hypertension · doi:10.1161/hypertensionaha.125.25112 · Cited by 13
Shah, M. U., Roebuck, A., Srinivasan, B., Ward, J. K., Squires, P. E., Hills, C. E., & Lee, K. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1499681 · Cited by 24
Martos, N., Vergara, A., Llorens-Cebrià, C., Motto, A. E., Martínez-Díaz, I., Gonçalves, F., Garcias-Ramis, M. M., Allo-Urzainqui, E., Narváez, A., Bermejo, S., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1415879 · Cited by 13
The evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 19
“Evidence for organ protection also extends to the kidney, with GLP1R and GLP1–GIPR agonists showing benefits on chronic kidney disease end points 16,118,284,285 .”
Sinclair, M. R., Ardehali, M. M., Diamantidis, C. J., & Corsino, L. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1412874 · Cited by 10
Diker‐Cohen, T., Rudman, Y., Turjeman, ., Akirov, A., Steinmetz, T., Calvarysky, B., & Dotan, I. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101624 · Cited by 16
Glucagon-like peptide-1 receptor agonists to improve cardiorenal outcomes: data from FLOW and beyond
Faruque, L. I., Yau, K., & Cherney, D. Z. I. (2025) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001066 · Cited by 12
Innovative therapeutics for renoprotection: Where we are
Cortinovis, M., Perico, N., & Remuzzi, G. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100060 · Cited by 10
Sato, A., & Nishimoto, M. (2025) · Hypertension Research · doi:10.1038/s41440-025-02175-2 · Cited by 14
Integrated primary and secondary care optimizes the management of people with CKD—the LUCID project
Major, R., Lakhani, N., Ahmed, Y., Atkin, J., Baines, R. J., Balment, R., Cheung, C. K., Graham-Brown, M. P. M., Ellwood, C. N., Harding, L., et al. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf049 · Cited by 10
Weiskirchen, R., & Lonardo, A. (2025) · Medical Sciences · doi:10.3390/medsci13040265 · Cited by 22
Clinical Assessment of People With Obesity: Focus on Adiposity-Related Multimorbidity
Bianchettin, R. G., Gawey, B. J., Acosta, A. J., Borlaug, B. A., Caples, S. M., Collazo–Clavell, M. L., Clark, M. M., Lara-Breitinger, K. M., Lerman, A., Lerman, L. O., et al. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.02.021 · Cited by 16
Moreira, R. O., Valério, C. M., Hohl, A., Moulin, C., Moura, F., Trujilho, F. R., Gerchman, F., Corrêa, L. L., Mancini, M. C., de Melo, M. E., et al. (2024) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2024-0422 · Cited by 29
“The study was interrupted pre-maturely due to efficacy, with the semaglutide 1.0 mg group demonstrating a 24% reduction in the primary outcome (141).”
InfluentialTran, D. T., Yeung, E. S. H., Hong, L. Y. Q., Kaur, H., Advani, S. L., Liu, Y., Syeda, M. Z., Batchu, S. N., & Advani, A. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01525-3 · Cited by 13
Wallace, H., Wick, J., Neuen, B. L., Buizen, L., Badve, S. V., Chalmers, J. P., Costa, J. D. O., Falster, M. O., Ha, J. T. K., Jardine, M., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16608 · Cited by 13
“3,5 Despite their known benefits, several international studies have reported low uptake of these therapies in patients with CKD 6 – 10 and have found a ‘ comorbidity paradox ’ where those with more co-morbidities who are more likely to derive benefit are less likely to be prescribed.”
Lam, C. S. P., Bozkurt, B., Cherney, D. Z. I., Ezekowitz, J. A., Jardine, M., Khan, S. S., Madero, M., Sarnak, M. J., ter Maaten, J. M., Cheung, M., et al. (2026) · Kidney International · doi:10.1016/j.kint.2025.10.011 · Cited by 16
Self-citationWang, J., Yang, J., Jiang, W., Liu, W., Shen, Z., Gao, Z., & Chang, B. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15860 · Cited by 10
“…shown in the FLOW trial, where semaglutide reduced the risk of major kidney disease events by 24% compared with placebo in people with T2D and CKD. 20 As per guidelines, recommendations for management of DKD include treatment of hypertension and glycaemia control, 2,4 as these factors have been…”
Bellos, I., Marinaki, S., Λάγιου, Π., & Benetou, V. (2024) · Biomolecules · doi:10.3390/biom15010039 · Cited by 12
Therapeutic Consequences and Prognostic Impact of Multimorbidity in Heart Failure: Time to Act
Bánfi‐Bacsárdi, F., Kazay, Á., Gergely, T. G., Forrai, Z., Füzesi, T. P., Hanuska, L. F., Schäffer, P. P., Pilecky, D., Vámos, M., Vértes, V., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm14010139 · Cited by 13
Berger, M., Marx, N., & Marx-Schütt, K. (2025) · European Cardiology Review · doi:10.15420/ecr.2024.29 · Cited by 16
“58 In addition, semaglutide treatment reduced MACE by 18% (HR 0.82; 95% CI [0.68–0.98]), CV mortality by 29% (HR 0.71; 95% CI [0.56–0.89]) and all-cause mortality by 20% (HR 0.80; 95% CI [0.67–0.95]).”
InfluentialEmerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on Semaglutide
Odigwe, C. I., Mulyala, R. R., Malik, H., Ruiz, B., Riad, M., Sayiadeh, M. A., Honganur, S., Parks, A., Rahman, M. U., & Lakkis, N. M. (2025) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2025.100518 · Cited by 17
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., Sadusky, T., et al. (2025) · Kidney International · doi:10.1016/j.kint.2024.12.019 · Cited by 12
Self-citationOstrominski, J. W., Chatur, S., & Vaduganathan, M. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae410 · Cited by 10
“…have also been shown to reduce kidney inflammation and preserve kidney structure and function—the latter demonstrated in the recent FLOW (Evaluate Renal Function with Semaglutide Once Weekly) trial 15 —which may be especially relevant for individuals with high decongestive therapy requirements.”
BackgroundSGLT2 Inhibitors in the Management of Cardio-Renal-Metabolic Syndrome: A New Therapeutic Era
Grigoriou, K., Karakasis, P., Nasoufidou, A., Stachteas, P., Klisic, A. N., Karagiannidis, E., Fyntanidou, B., Popovic, D. S., Patoulias, D., Antoniadis, A. P., et al. (2025) · Medicina · doi:10.3390/medicina61111903 · Cited by 23
“…effects, the FLOW trial involving 3533 patients with T2DM and CKD demonstrated that semaglutide reduced the incidence of the primary outcome by 24% compared to placebo, with consistent positive effects seen in kidney-related outcomes, CV death, eGFR decline, MACE, and overall mortality [178].”
Ruggiero, R., Longo, M., Mascolo, A., Nuzzo, M. D., Laino, L. V., Caruso, P., D'Amato, R., Rafaniello, C., Maiorino, M. I., Esposito, K., et al. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178004 · Cited by 12
COHEN, R. V., Azevedo, M. A., le Roux, C. W., Caldeon, L. P., Luque, A., Fayad, D. A., & Petry, T. B. Z. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07535-4 · Cited by 11
“However, over 25% of early discontinuation of semaglutide is secondary to suboptimal responders and/or side effects [57].”
Purcell, A. R., Zhen, X. M., Wong, J., & Glastras, S. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70188 · Cited by 13
Lee, Y., Wu, L., Wu, V., & Chang, C. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.03.016 · Cited by 16
Shirsat, P. D., Balachandran, M., Chamarthi, V. S., & Sonavane, K. (2025) · Journal of CardioRenal Medicine · doi:10.3390/jcrm1010004 · Cited by 17
“A landmark multi-nation trial by Perkovic et al. (FLOW trial) randomized 3533 participants with type 2 diabetes and CKD to receive subcutaneous semaglutide 1 mg weekly or placebo and studied the effects of semaglutide on kidney outcomes [53].”
Translational research on cognitive impairment in chronic kidney disease
Wagner, C. A., Massy, Z. A., Capasso, G., Mattace-Raso, F., Pépin, M., Bobot, M., Zoccali, C., Ferreira, A. C., Hoorn, E. J., Silva, P. H. I., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae229 · Cited by 16
Chu, L., Bradley, R. M., Auerbach, P., & Abitbol, A. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15834 · Cited by 12
“25 To the best of our knowledge, no real-world study has investigated the effectiveness of GLP-1 RAs compared with basal insulin among adults treated with mainstay SGLT2i therapy for T2D and CKD.”
Influential
Metadata
- Authors
- Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., & Pratley, R.
- Affiliations
- University of Copenhagen (DK)
- Novo Nordisk A/S, Søborg, Denmark.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-07-11
- Volume
- 391
- Issue
- 2
- Pages
- 109-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4398781461
- Cited by
- 2,099
- References
- 23
- Citations by year
- 2026: 953 · 2025: 863 · 2024: 281
- FWCI
- 551.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- semaglutide, chronic kidney disease, type 2 diabetes, renal failure, estimated glomerular filtration rate decline, cardiovascular mortality, albuminuria, GLP-1 receptor agonists, renal protection, cardiovascular outcomes, albumin-creatinine ratio, kidney transplantation, dialysis, anemia of chronic kidney disease, diabetic nephropathy, SGLT2 inhibitors
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Glucagon-Like Peptides, Female, Glomerular Filtration Rate, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.